Short Interest in IceCure Medical Ltd (NASDAQ:ICCM) Declines By 9.2%

IceCure Medical Ltd (NASDAQ:ICCM) was the recipient of a significant decline in short interest in the month of September. As of September 15th, there was short interest totalling 393,100 shares, a decline of 9.2% from the August 31st total of 432,900 shares. Currently, 1.7% of the company’s stock are short sold. Based on an average daily trading volume, of 542,000 shares, the short-interest ratio is currently 0.7 days.

IceCure Medical Stock Up 2.4 %

ICCM stock traded up $0.01 during mid-day trading on Friday, hitting $0.62. The stock had a trading volume of 414,544 shares, compared to its average volume of 518,096. The company has a current ratio of 2.97, a quick ratio of 2.54 and a debt-to-equity ratio of 0.03. IceCure Medical has a 1-year low of $0.54 and a 1-year high of $1.57. The company has a fifty day moving average of $0.66 and a 200 day moving average of $0.90. The stock has a market capitalization of $28.51 million, a price-to-earnings ratio of -1.89 and a beta of 0.56.

IceCure Medical (NASDAQ:ICCM) last issued its earnings results on Tuesday, August 20th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. IceCure Medical had a negative return on equity of 111.27% and a negative net margin of 410.22%. The company had revenue of $1.01 million for the quarter, compared to analyst estimates of $0.90 million. During the same period in the prior year, the firm posted ($0.09) EPS. On average, equities analysts expect that IceCure Medical will post -0.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in IceCure Medical stock. Renaissance Technologies LLC acquired a new stake in shares of IceCure Medical Ltd (NASDAQ:ICCM) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned about 0.15% of IceCure Medical as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 0.62% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $2.50 price target on shares of IceCure Medical in a research report on Thursday, September 12th.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.